Accidental IV Bentyl Administration Management
Immediately discontinue the infusion, contact poison control (1-800-222-1222), monitor closely for anticholinergic toxicity and thrombotic complications, and consider prophylactic anticoagulation if thrombosis develops.
Immediate Actions
The accidental IV administration of dicyclomine (Bentyl) requires urgent intervention due to two primary risks: anticholinergic toxicity and thrombosis. Bentyl is NOT approved for IV administration and carries significant risk of vascular complications 1.
Monitor for Anticholinergic Toxicity
Watch for the following signs and symptoms of overdose 1:
- Central nervous system: CNS stimulation, convulsions, confusion, drowsiness
- Cardiovascular: Tachycardia, dilated pupils
- Autonomic: Hot dry skin, dry mouth, difficulty swallowing, blurred vision
- Neuromuscular: Curare-like action with muscular weakness and possible paralysis
- Gastrointestinal: Nausea, vomiting, headache, dizziness
Assess for Thrombotic Complications
The most critical complication unique to IV dicyclomine is thrombosis 2. A 2025 case report documented both non-occlusive axillary vein thrombosis and occlusive superficial basilic vein thrombosis following inadvertent IV administration. The mechanism involves:
- M3 receptor inhibition leading to nitric oxide suppression
- Promotion of a pro-thrombotic state
- Potential for both superficial and deep vein thrombosis
Obtain vascular ultrasound of the affected extremity to evaluate for thrombosis, particularly if the patient develops:
- Arm swelling
- Pain at injection site
- Erythema or warmth
- Palpable cord
Treatment Algorithm
Step 1: Supportive Care
- Discontinue infusion immediately
- Establish IV access in contralateral extremity
- Monitor vital signs continuously
- Contact poison control center (1-800-222-1222) 3, 1
Step 2: Anticholinergic Toxicity Management
Per FDA labeling 1:
- Sedatives (short-acting barbiturates or benzodiazepines) for signs of excitement or agitation
- Parenteral cholinergic agent as antidote if indicated for severe anticholinergic symptoms
- Note: Gastric lavage, emetics, and activated charcoal are NOT applicable for IV administration
Step 3: Thrombosis Management
If ultrasound confirms thrombosis 2:
- Initiate therapeutic anticoagulation (enoxaparin or rivaroxaban based on the 2025 case report)
- Duration should follow standard DVT treatment protocols
- Consider hematology consultation for complex cases
Step 4: Monitoring Duration
- Minimum 24-hour observation for anticholinergic symptoms
- Serial neurovascular checks of affected extremity
- Repeat ultrasound if clinical suspicion develops even with initial negative study
Critical Pitfalls to Avoid
Do not assume symptoms are benign: Even if initial presentation seems mild, thrombotic complications may develop hours after administration 2
Do not delay ultrasound: The 2025 case demonstrated that thrombosis can occur rapidly and may be both superficial and deep
Dialysis is not effective: Dicyclomine is not known to be dialyzable 1, so supportive care and symptom management are paramount
Do not use flumazenil: While the AHA guideline 3 mentions flumazenil for benzodiazepine toxicity, this is NOT indicated for anticholinergic toxicity and may worsen seizures
System-Level Prevention
Following this incident, implement 2:
- Barcode medication administration system review
- Clear labeling that dicyclomine is NEVER for IV use
- Adverse drug event reporting to FDA MedWatch
- Staff education on proper administration routes
The evidence strongly supports that IV dicyclomine administration is a medical emergency requiring immediate intervention, close monitoring, and vascular imaging to prevent potentially serious thrombotic complications that may not be immediately apparent.